Verona Pharma And Ritedose Partner To Deliver First-In-Class COPD Drug, Ohtuvayre
Verona Pharma And Ritedose Partner To Deliver First-In-Class COPD Drug, Ohtuvayre
-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of COPD.
Ritedose是Ohtuvayre（ensifentrine）的開發合作伙伴和製造商，這是20多年來首個具有新機制作用的吸入產品，用於COPD的維持治療。
COLUMBIA, S.C., Sept. 17, 2024 /PRNewswire/ -- The Ritedose Corporation, Inc. (Ritedose), the largest CDMO in the United States specializing in sterile Blow Fill Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is proud to partner with Verona Pharma plc (NASDAQ:VRNA) as the development and manufacturing partner of Ohtuvayre, a new novel product for Chronic Obstructive Pulmonary Disease (COPD).
南卡羅來納州哥倫比亞，2024年9月17日/美通社/ - Ritedose Corporation, Inc.（Ritedose）是美國最大的CDMO，專門從事眼科和呼吸市場的無菌吹填封（BFS）單劑量溶液的生產，以與Verona Pharma plc（納斯達克：VRNA）合作，作爲Ohtuvayre的開發和製造合作伙伴，這是一種用於慢性阻塞性肺疾病（COPD）的新型產品。
譯文內容由第三人軟體翻譯。